TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

Resources

TransCode Founder's Publications

Linked references in italics below are authored by TransCode's scientific co-founders
  • Anna Moore, N A. Savan,  Paulo V. Saavedra, Alan Halim, Vilma Yuzbasiyan-Gurkan, Ping Wang, Byunghee Yoo, Matti Kiupel, Lorenzo Sempere, Zdravka Medarova: Case Report: microRNA-10b as a Therapeutic Target in Feline Metastatic Mammary Carcinoma and its Implications for Human Clinical Trials. Frontiers in Oncology October 26, 2022 12:959630
  • Le Fur et al.,: Radiolabeling and PET–MRI micro-dosing of the experimental cancer therapeutic, MN‑anti‑miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer. Cancer Nanotechnology 2021;12(1):16.
  • Byunghee Yoo, Alana Ross, Pamela Pantazopoulos & Zdravka Medarova: miRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer, Scientific Reports volume 11, Article number: 2844 (2021)
  •  Sheedy, P, Medarova, Z: The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res 2018;8(9):1674-1688.
  • Yoo B, Greninger P, Stein GT, Egan RK, McClanaghan J, Moore A, et al. (2018) Potent and selective effect of the mir-10b inhibitor MN-anti- mir10b in human cancer cells of diverse primary disease origin. PLoS ONE 13(7): e0201046 2018.
  • Yoo B, Fuchs BC and Medarova Z: New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology Volume 8, Article 258, July 2018
  • Yoo B, Kavishwar, A, Wang, P, Ross, A, Pantazopoulos,P Dudley, M, Moore, A, & Medarova, Z: Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer. Scientific Reports 21 March 2017 7:45060 | DOI: 10.1038/srep45060.
  • Yoo B, Kavishwar A, Ross A, Wang P, Tabassum DP, Polyak K, Barteneva N, Petkova V, Pantazopoulos P, Tena A, Moore A, Medarova Z: Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Res 2015, 75:4407-4415.​
  • Yoo B, Kavishwar A., Ghosh SK, Barteneva N, Yigit MV, Moore A. Medarova Z.: Detection of miRNA Expression in Intact Cells Using Activatable Sensor Oligonucleotides. Chemistry & Biology 21, 199–204, February 20, 2014
  • Yoo B, Ghosh SK, Kumar M, Moore A, Yigit MV, Medarova Z: Design of nanodrugs for miRNA targeting in tumor cells. J Biomed Nanotechnol 2014;10:1114-1122​
  • Yigit MV, Ghosh SK, Kumar M, Petkova V, Kavishwar A, Moore A, Medarova Z: Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis. Oncogene 2013;32:1530-1538​​

Other Relevant Publications

  • Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-688
  • Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A: MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-221
  • Moriarty CH, Pursell B, Mercurio AM: miR-10b Targets Tiam1: impications for Rac activation and carcinoma migration. J Biol Chem 2010;285:20541-20546
  • Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z: MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 2010;285:7986-7994
  • Ma L, Reinhardt F, Pan E, Soutschek Jr, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010;28:341-347
  • Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, Kefas B, Godlewski J, Schiff D, Purow B: Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol 2013:1-11
  • Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM, Tannous BA, Krichevsky AM: Human glioma growth is controlled by microRNA-10b. Cancer Res 2011;71:3563-3572
  • Huang Q, Song Q, Zhong W, Chen Y, Liang L. MicroRNA-10b and the clinical outcomes of various cancers: A systematic review and meta-analysis. Clin Chim Acta. 2017; 474:14-22​
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7–30.
  • Hamilton, BE et al: Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. J Neurooncol. 2016 Sep;129(2):301-9.
  • Ma, L et al, Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways. Cancer Res; 76(21) November 1, 2016.​

Posters

  • Oligonucleotide Therapeutics Society 2022 Poster

Downloadable Information Sheets

  • Decoding the Major Challenge of RNA Delivery
  • Advancing New RNA Therapies Through a Modular Approach
  • Lead Candidate TTXMC-138
  • TTX-siPDL1
  • 64Cu-TTX-MC138
  • TTX-RIGA
  • TTX-siLIN28B
  • ​Diagnostic Approaches for Early Cancer Detection
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers